CanAm Bioresearch is a contract research organization (CRO) engaged in pre-clinical discovery and development, particularly focused on medicinal chemistry.
EpiTherapeutics R&D EVP Lars-Ole Gerlach said they are very pleased to enter into a formalized drug discovery collaboration with CanAm, after working with their team for the past several months.
"We look forward to a fruitful collaboration with the aim of developing novel anti-cancer drugs within the promising new area of epigenetics," Gerlach said.